Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, March 2009, p. 1157-1164, Vol. 53, No. 3
0066-4804/09/$08.00+0 doi:10.1128/AAC.01237-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Institute of Life Science, Swansea University, Swansea, Wales, United Kingdom,1 Cancer Biomarkers and Prevention Group, RKCSB, Leicester Royal Infirmary, Leicester, United Kingdom2
Received 17 September 2008/ Returned for modification 18 October 2008/ Accepted 7 December 2008
The genome sequence of Mycobacterium leprae revealed a single open reading frame, ML2088 (CYP164A1), encoding a putative full-length cytochrome P450 monooxygenase and 12 pseudogenes. We have identified a homolog of ML2088 in Mycobacterium smegmatis and report here the cloning, expression, purification, and azole-binding characteristics of this cytochrome P450 (CYP164A2). CYP164A2 is 1,245 bp long and encodes a protein of 414 amino acids and molecular mass of 45 kDa. CYP164A2 has 60% identity with Mycobacterium leprae CYP161A1 and 66 to 69% identity with eight other mycobacterial CYP164A1 homologs, with three identified highly conserved motifs. Recombinant CYP164A2 has the typical spectral characteristics of a cytochrome P450 monooxygenase, predominantly in the ferric low-spin state. Unusually, the spin state was readily modulated by increasing ionic strength at pH 7.5, with 50% high-spin occupancy achieved with 0.14 M NaCl. CYP164A2 bound clotrimazole, econazole, and miconazole strongly (Kd, 1.2 to 2.5 µM); however, strong binding with itraconazole, ketoconazole, and voriconazole was only observed in the presence of 0.5 M NaCl. Fluconazole did not bind to CYP164A2 at pH 7.5 and no discernible type II binding spectrum was observed.
Published ahead of print on 15 December 2008.
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»